| NAME |
OLUTASIDENIB 150MG CAP,ORAL |
| VA GENERIC NAME |
OLUTASIDENIB |
| DOSAGE FORM |
CAP,ORAL |
| FDA MED GUIDE |
Olutasidenib_(Rezlidhia)_(2022).pdf |
| HAZARDOUS TO DISPOSE |
NO |
| ACTIVE INGREDIENTS |
|
| CS FEDERAL SCHEDULE |
Unscheduled |
| STRENGTH |
150 |
| SINGLE/MULTI SOURCE PRODUCT |
Single source |
| UNITS |
MG |
| NATIONAL FORMULARY NAME |
OLUTASIDENIB CAP,ORAL |
| CREATE DEFAULT POSSIBLE DOSAGE |
NO |
| POSSIBLE DOSAGES TO CREATE |
1x Possible Dosage |
| PACKAGE |
Both Inpatient and Outpatient |
| CODING SYSTEM |
|
| COPAY TIER |
-
- COPAY TIER LEVEL: 3
- COPAY EFFECTIVE DATE: 2022-12-15 00:00:00
|
| PGX ELIGIBLE |
NO |
| PGX SUPPRESSED |
NO |
| VA PRINT NAME |
OLUTASIDENIB 150MG ORAL CAP |
| VA PRODUCT IDENTIFIER |
O0443 |
| TRANSMIT TO CMOP |
NO |
| VA DISPENSE UNIT |
CAP |
| MASTER ENTRY FOR VUID |
YES |
| VUID |
4041887 |
| EFFECTIVE DATE/TIME |
-
- 2022-12-15 00:00:00
- STATUS: ACTIVE
|
